Mark Ragosa - Apr 26, 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Apr 26, 2024
Transactions value $
-$9,101
Form type
4
Date filed
4/30/2024, 04:35 PM
Previous filing
Apr 8, 2024
Next filing
Jul 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +991 +5.28% 19.8K Apr 26, 2024 Direct F1
transaction KNSA Class A Common Share Tax liability -$9.1K -509 -2.58% $17.88 19.3K Apr 26, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 +991 $0.00 990 Apr 26, 2024 Class A Common Share 991 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021.